

ON-LINE FIGURE. Latest BCVI screening and management guideline⁴ as suggested by Denver Health Medical Center group. Reprinted from: Geddes AE, Burlew CC, Wagenaar AE, et al. Expanded screening criteria for blunt cerebrovascular injury: a bigger impact than anticipated. *Am J Surg* 2016;212:1167–74, with permission from Elsevier.

On-line Table 1: Neck CT angiography protocol for BCVI screening at our institution

Protocol	
Scan range	Aortic arch to the skull base (aortic arch to circle of Willis)
Scan parameters	120 kV and automated milliampere
Contrast	Iopamidol 370 ^a
Contrast dose (depends on eGFR)	100 mL (eGFR > 60)
	75 mL (eGFR $> 30 \le 60$)
	Followed by 40-mL saline at 4 mL/s
Injection rate	4 mL/s through 18- to 20-ga cannula
Section thickness	3 mm (overlap of 2.5 mm) and 1 \times 0.7, sent to 3D workstations

Note:—eGFR indicates estimated glomerular filtration rate.

On-line Table 2: Neck MR angiography protocol for BCVI screening at our institution

00171	
Protocol	
Position and scan range	Supine, aortic arch to the circle of Willis
Contrast	Gadavist ^a
Contrast dose	0.1 mL/kg (or 0.1 mmol/kg) intravenous
Technique	Axial TI fat-saturated
	Axial T2
	Axial 2D time-of-flight MRA
	3D MRA using a 3D gradient-echo pulse sequence with
	fat suppression (also sent to 3D workstation)
Injection rate	1.5–2 mL/s
Saline bolus	10 mL at 2 mL/s

^a Gadobutrol (Bayer Schering Pharma, Berlin, Germany).

^a Imeron (Bracco, Milan, Italy).